GlobeNewswire

eGain Corporation :Consumers Say No to Chatbot Silos in US and UK Survey

Dela

Independent survey of 3000 consumers by Chatbots.org reveals that lack of integration with human-assisted service is the biggest pain point in using virtual assistants

SUNNYVALE, Calif. and NEWBURY, United Kingdom, Feb. 07, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced that chatbot silos are the biggest hurdle for consumers in using virtual assistants. The finding is from an independent survey of 3,000 consumers, conducted by Chatbots.org.

Established in 2008, Chatbots.org is a global community devoted to the promotion of AI for business and societal value. The organization collaborates with businesses and academic institutions, sharing new developments in AI technologies such as chatbots and reasoning, and propagating best practices in leveraging them.

Sponsored by eGain, the research was conducted by Chatbots.org in Q4 calendar 2017 across the US and the UK, using SurveyMonkey(TM). Responses were compiled from 3,000 consumers who had used a chatbot for customer service in the prior 12 months. Key findings and corresponding viewpoints from Chatbots.org and eGain are:

  • 59% of respondents (62% in the US and 55% in the UK) found that having to repeat information and context to a human agent in the event of escalation from chatbots was the biggest hassle by far in using virtual assistants1Not surprisingly, this is a result of chatbot deployments that are completely disconnected from agent-assisted touchpoints.
  • The second biggest deterrent at 32% (29% US and 37% UK) was chatbots "getting stuck and not knowing what to do next." This is a common problem that arises from a lack of focus on knowledge management to empower chatbots.
  • 53% of the consumers surveyed (54% US and 52% UK) found chatbots to be "not effective" or only "somewhat effective." US consumers were harsher in their assessment of chatbots with 14% rating them as not effective versus only 5% of UK consumers. This is perhaps an indication that US consumers are challenging chatbots with more complex questions than UK consumers.
  • Younger consumers thought that chatbots were more effective-where 22% of Generation Z and 15% of millennials rated them as "very effective," only 12% of boomers and the silent generation gave them the same rating. This is likely due to the positive attitude that digitally savvy Gen Z and millennial consumers have towards chatbots.
  • Consumers with higher education found chatbots to be twice as ineffective as the less educated consumers did-13% of respondents with undergraduate or graduate degrees rated chatbots as "not effective" versus 7% of those with high school diplomas or incomplete high school education. This could be because educated consumers challenge chatbots to resolve more complex service problems.

"We wanted to understand the barriers consumers face in using chatbots in order to promote their adoption," said Erwin van Lun, CEO and founder of Chatbots.org. "The survey findings will help technology providers improve their offerings while helping businesses select and deploy chatbots the right way to make it easy for consumers."

"eGain is a pioneer in chatbot and AI technology with over 20 years of experience in the domain," said Ashu Roy, eGain CEO. "The survey validates our vision of unifying chatbots and other touchpoints through a customer engagement hub to enable seamless, omnichannel customer service journeys."

More Information

An infographic containing key findings can be downloaded at http://www.egain.com/resources/egain-chatbot-survey-2018/.

To learn more about eGain Virtual Assistant and other AI knowledge solutions, visit:

http://www.egain.com/products/virtual-assistant-software/

http://www.egain.com/products/knowledge-management-software/

http://www.egain.com/products/web-self-service/

http://www.egain.com/try-buy

About Chatbots.Org

Chatbots.org is an international platform for vendors, users and developers of chatbots for customer service, e-commerce and marketing. Erwin van Lun, CEO of Chatbots.org, founded the community after he predicted that chatbots will gradually become the #1 customer communication channel for brands in his (Dutch) book 'Van Massamerk naar Mensmerk' in 2005. He has given over a hundred speeches in eight countries since.

About eGain

eGain customer engagement solutions power digital transformation for leading brands. Our top-rated cloud applications for social, mobile, web, and contact centers help clients deliver connected customer journeys in an omnichannel world. To find out more about eGain, visit http://www.egain.com.

eGain, the eGain logo, and all other eGain product names and slogans are trademarks or registered trademarks of eGain Corp. in the United States and/or other countries. All other company names and products mentioned in this release may be trademarks or registered trademarks of the respective companies.

eGain media contact

Corporate
Tim Cox

ZingPR on behalf of eGain
Tim@ZingPR.com 

Europe
Jane Stewart 
Phone: +44 (0)1635 800087, Ext. 5118
Email: press@egain.com 

_____________________

1 Consumers were asked to select up to two hurdles.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: eGain Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum